3/5
08:28 am
crvo
CervoMed (CRVO) had its "buy" rating reaffirmed by Chardan Capital. They now have a $15.00 price target on the stock.
Low
Report
CervoMed (CRVO) had its "buy" rating reaffirmed by Chardan Capital. They now have a $15.00 price target on the stock.
3/5
07:30 am
crvo
CervoMed to Participate in Upcoming Investor Conferences
Low
Report
CervoMed to Participate in Upcoming Investor Conferences
3/4
02:49 pm
crvo
CervoMed (CRVO) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $31.00 price target on the stock.
Low
Report
CervoMed (CRVO) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $31.00 price target on the stock.
3/4
07:30 am
crvo
CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies
Medium
Report
CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies
2/18
08:13 am
crvo
CervoMed (NASDAQ:CRVO) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $31.00 price target on the stock.
Medium
Report
CervoMed (NASDAQ:CRVO) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $31.00 price target on the stock.
2/18
06:00 am
crvo
CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform designed to prioritize promising treatments for Amyotrophic Lateral Sclerosis
Medium
Report
CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform designed to prioritize promising treatments for Amyotrophic Lateral Sclerosis
2/6
05:33 pm
crvo
CervoMed (NASDAQ:CRVO) was upgraded by analysts at Brookline Cap M to a "strong-buy" rating.
Medium
Report
CervoMed (NASDAQ:CRVO) was upgraded by analysts at Brookline Cap M to a "strong-buy" rating.
2/5
06:09 am
crvo
CervoMed (NASDAQ:CRVO) was upgraded by analysts at Brookline Capital Management to a "strong-buy" rating.
Medium
Report
CervoMed (NASDAQ:CRVO) was upgraded by analysts at Brookline Capital Management to a "strong-buy" rating.
12/18
08:05 am
crvo
CervoMed (NASDAQ:CRVO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
Low
Report
CervoMed (NASDAQ:CRVO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
12/18
07:11 am
crvo
CervoMed (NASDAQ:CRVO) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
Medium
Report
CervoMed (NASDAQ:CRVO) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.